Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study.


Kose M., Emet S., Akpinar T. S., Kocaaga M., Cakmak R., AKARSU M., ...Daha Fazla

Angiology, cilt.66, sa.8, ss.727-31, 2015 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 66 Sayı: 8
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1177/0003319714548870
  • Dergi Adı: Angiology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.727-31
  • Anahtar Kelimeler: endocan, endothelial-specific molecule 1, acute coronary syndrome, Gensini score, coronary artery disease, SYNTAX score, CELL SPECIFIC MOLECULE-1, VEGF-A, CANCER, ANGIOGENESIS, EXPRESSION, MARKER, GENE
  • İstanbul Üniversitesi Adresli: Evet

Özet

Endothelial-specific molecule 1 (endocan) is expressed in endothelial cells. We investigated the relationship between acute coronary syndrome (ACS) and serum endocan levels. We included 30 individuals as a control group and 53 patients diagnosed with ACS. The severity of coronary artery disease was assessed by a modified Gensini stenosis and SYNTAX scoring system. There was a significant difference in serum endocan levels between the control group and the ACS group (0.75 +/- 0.13 vs 0.86 +/- 0.25 ng/mL, P = .014). There was also a significant difference in serum endocan levels between diabetic patients with ACS and nondiabetic patients with ACS (1.02 +/- 0.33 vs 0.81 +/- 0.21 ng/mL, P = .016). There was no significant correlation between serum endocan level, Gensini, and SYNTAX score (r = .11, P = .53 and r = .16, P = .37). Endocan, a new biomarker of endothelial pathology, is significantly increased in patients with ACS.